| Literature DB >> 24872894 |
Vaibhav Rastogi1, Pragya Yadav1, Shiv Sankar Bhattacharya1, Arun Kumar Mishra1, Navneet Verma1, Anurag Verma1, Jayanta Kumar Pandit2.
Abstract
During recent years carbon nanotubes (CNTs) have been attracted by many researchers as a drug delivery carrier. CNTs are the third allotropic form of carbon-fullerenes which were rolled into cylindrical tubes. To be integrated into the biological systems, CNTs can be chemically modified or functionalised with therapeutically active molecules by forming stable covalent bonds or supramolecular assemblies based on noncovalent interactions. Owing to their high carrying capacity, biocompatibility, and specificity to cells, various cancer cells have been explored with CNTs for evaluation of pharmacokinetic parameters, cell viability, cytotoxicty, and drug delivery in tumor cells. This review attempts to highlight all aspects of CNTs which render them as an effective anticancer drug carrier and imaging agent. Also the potential application of CNT in targeting metastatic cancer cells by entrapping biomolecules and anticancer drugs has been covered in this review.Entities:
Year: 2014 PMID: 24872894 PMCID: PMC4020363 DOI: 10.1155/2014/670815
Source DB: PubMed Journal: J Drug Deliv ISSN: 2090-3022
Figure 1Carbon nanotube: (a) single walled carbon nanotube and (b) multiwalled carbon nanotube.
Figure 2Schematic representation of methods used for carbon nanotube synthesis: (a) Arc discharge method, (b) chemical vapour deposition method, (c) laser ablation method.
Figure 3Mechanism of carbon nanotube synthesis: (a) Arc discharge method, (b) chemical vapor deposition method, and (c) laser ablation method.
Figure 4Schematic illustration of functionalization of CNTs with various molecules: (a) Prakash et al. [18], (b) Xiao et al. [78], (c) Xu et al. [70], (d) Gomez-Gualdron et al. [64], (e) Bianco et al. [79], (f) Jiang et al. [80], (g) Williams et al. [81], and (h) Kam and Dai [82].
Figure 5Pathways for the penetration of CNTs into the cell. (a) Nonreceptor mediated endocytosis: (1) membrane that surrounds the drug loaded functionalized CNTs, (2) internalization of drug loaded CNTs, and (3) release of drug; (b) receptor mediated endocytosis: (4) membrane surrounds the CNT-receptor conjugate by forming endosomes followed by internalization, (5) release of drug, and (6, 7, 8) regeneration of receptor; (c) endocytosis independent pathway: (9) direct penetration of drug loaded functionalized CNT and (10) release of the drug.
Impact of functionalized CNTs on cancer cell lines.
| Cancer type | CNT properties | Bioactive molecule | Objective | Cell line | Repercussion of the study | Reference | |
|---|---|---|---|---|---|---|---|
| Type | Functionalization | ||||||
| Brain | MWCNTs | — | — | Influence of purity and surface oxidation on cytotoxicity of MWCNTs with human neuroblastoma cells | Human neuroblastoma cell line SH-SY5Y | With prolonged cultures, loss of cell viability was minimal for preparations with 99% purity, but significant adverse effects were detected with 97% purity and with acid treated preparations. A concentration of 5–10 | [ |
| SWCNTs | Phospholipid-polyethylene glycol (PEG), protein A, fluorescein labeled integrin | — | Functional SWCNTs based on an integrin | Human U-87MG glioblastoma cell, MCF-7 | In vitro study revealed that SWCNT-PEG-mAb presented a high targeting efficiency on integrin | [ | |
| MWCNTs | Angiopep-2, PEGylated | Doxorubicin | Targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized MWCNTs modified with angiopep-2. | C6 glioma cells | Angiopep-2 modified PEGylated MWCNTs showed better antiglioma activity, good compatibility, and low toxicity. | [ | |
| MWCNTs | Poly(acrylic acid) and folic acid | Doxorubicin | Dual targeted delivery of doxorubicin to cancer cells using folate conjugated magnetic MWCNTs. | U87 human glioblastoma cells | Dual targeting of doxorubicin from magnetic MWCNTs showed enhanced cytotoxicity toward U87 human glioblastoma cells compared with free doxorubicin. | [ | |
| SWCNTs | CD133 monoclonal antibody (mAB) | — | Photothermolysis of glioblastoma stem like cells targeted by CNT conjugated with CD133 mAB. | GBM-CD133+ and GBM-CD133− cells | GBM-CD133+ cells were selectively targeted and eradicated whereas CD133− cells remained viable after incubation with SWCNT-CD133mAB. GBM-CD133+ cells pretreated with SWCNT-CD133mAB and irradiated by near-infrared laser for 2 days did not exhibit sustainability of cancer stem like cells features for tumor growth. | [ | |
| MWCNTs | — | SiRNA and DNA | Internalization of MWCNTs by microglia: possible application in immunotherapy of brain tumors. | BV2 microglia and GL261 glioma cells | Uptake of MWCNTs by both BV2 and GL261 cells in vitro without any significant signs of cytotoxicity. | [ | |
|
| |||||||
| Blood | SWCNTs | Sgc8c aptamer | Daunorubicin (Dau) | Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped CNTs | Human T cell leukemia cell MOLT-4 and U266 myeloma cells | The tertiary complex Dau-aptamer-SWCNTs was internalized effectively to MOLT-4 cells but not to U266 cells and is less toxic in U266 as compared to Dau-aptamer-SWCNTs complex is able to selectively target MOLT-4 cells | [ |
|
| |||||||
| Breast | SWCNTs | Polyethylene glycol (PEG) and Poly (maleic anhydride-alt-1-octadecene) (PMHC18) | — | Optimization of surface chemistry on single walled CNTs for in vivo photothermal ablation of tumors | Balb/c mice bearing 4T1 tumors | PEG-PMHC18-SWCNTs showed ultralong blood circulation half-lives though showing high uptake in the tumor tend to accumulate in the skin dermis | [ |
| MWCNTs | Polyamidoamine dendrimer(d) | FITC-labelled antisense c-myc oligonucleotides (asODN) | Synthesis and characterization of polyamidoamine dendrimer coated MWCNTs and their application in gene delivery systems | MCF-7 and MDA-MB-435 human breast cancer cell line, liver cancer cell HepG2 | Laser confocal microscopy confirmed the entry of asODN into the tumor cell, within 15 min of incubation. asODN-dMNTs composites inhibit the cell growth and downregulated the expression of the c-myc gene and C-Myc protein. | [ | |
| SWCNTs | Insulin-like growth factor 1 receptor (IGF 1R-) specific and nonspecific monoclonal antibodies (mABs) | — | Bioconjugated CNTs for targeting cancer biomarkers | BT-474 and MCF-7 breast cancer cells | mAB-CNT as field effect transistors are very promising biosensor candidates to detect cancer cells. | [ | |
| SWCNTs | Distearoylphosphatidy-lethanolamine (DSPE)-PEG-Amine, mouse double minute 2 homolog (MDM2) | SiRNA | Functionalized SWCNTs enables efficient intracellular delivery of SiRNA targeting MDM2 to inhibit breast cancer cells growth | B-Cap-37 breast carcinoma cells | f-SWCNTs showed significant efficiency in carrying SiRNA and SiRNA-MDM2 complexes in B-Cap-37 cells and caused inhibition of proliferating cells. | [ | |
| SWCNTs | — | — | SWCNT nanobomb agents for killing breast cancer cells. | Human BT-474 breast cancer cells | SWCNT-based systems were capable of killing cancer cells without causing toxicity to the surrounding cells. | [ | |
| SWCNTs | Polyethylene glycol | Paclitaxel | Drug delivery with CNTs for in vivo cancer treatment | 4T1 murine breast cancer cell line | SWCNT-PTX affords higher efficacy in suppressing tumor growth without causing obvious toxic effects to normal organs. | [ | |
| SWCNTs | anti-HER2 chicken IgY antibody | — | Anti-HER2 IgY antibody-functionalized SWCNTs for detection and selective destruction of breast cancer cells | HER2-expressing SK-BR-3 cells and HER2-negative MCF-7 cells | Raman signal collected at single-cell level from the complex-treated SK-BR-3 cells was significantly greater than that from various control cells. HER2 IgY-SWCNT complex specifically targeted HER2-expressing SK-BR-3 cells but not receptor-negative MCF-7 cells. | [ | |
|
| |||||||
| Colon | MWCNTs | — | — | Vertically aligned MWCNTs to preferentially entrap highly metastatic cancer cells | SW-48 cells and HT-29 human colon adenocarcinoma cell | Vertically aligned MWCNT entrap higher metastatic cancer in larger fraction than lower metastatic grades. Cell rigidity due to fixation decreases the entrapment efficiency | [ |
|
| |||||||
| Colon | SWCNTs | Bovine serum albumin-antibody, fluorescein | Doxorubicin | Triple functionalization of SWCNTs with doxorubicin, a monoclonal antibody and a fluorescent marker for targeted cancer therapy | WiDr Human colon adenocarcinoma cells | The triple fictionalized complex was efficiently taken by cancer cells with subsequent intracellular release of doxorubicin. | [ |
|
| |||||||
| Liver | MWCNTs | Polyamidoamine dendrimer(d) | FITC-labelled antisense c-myc oligonucleotides (asODN) | Synthesis and characterization of polyamidoamine dendrimer coated MWCNTs and their application in gene delivery systems | HEP-G2 human hepatoma cells | Laser confocal microscopy confirmed the entry of asODN into the tumor cell, within 15 min of incubation. asODN-dMNTs composites inhibit the cell growth and downregulated the expression of the c-myc gene and C-Myc protein. | [ |
| SWCNTs | Chitosan and folic acid | Doxorubicin | Targeted DDS based on chitosan and folic acid modified SWCNTs for controllable loading/release of anticancer agent doxorubicin. | Hepatocellular carcinoma SMMC-7721 cell lines | The chitosan-folic acid modified SWCNTs not only kill cancer cells efficiently, but also display much less in vivo toxicity than free doxorubicin. | [ | |
|
| |||||||
| Lymph node Metastatis | MWCNTs | Magnetic | Gemcitabine (GEM) | Magnetic functionalized CNTs as drug vehicles for cancer lymph node metastasis treatment | BxPC-3 pancreatic cancer cells | mMWCNTs-GEM had high antitumor activity resulting in successful regression and inhibition of lymph node metastasis under the magnetic field. | [ |
|
| |||||||
| Kidney | SWCNTs | — | — | Effect of SWCNTs on human HEK293 cells | Human kidney embryo cell HEK-293 cells | SWCNTs inhibit HEK293 cell proliferation and decrease cell adhesive ability in a dose and time dependent manner. | [ |
| SWCNTs | Phenosafranine (PS) and Nile blue (NB) dyes | — | SWCNTs modified with organic dyes: synthesis, characterization, and potential cytotoxic effects | Baby hamster kidney fibroblast cells BHK-21 cell line | Cytotoxicity of dye modified SWCNT displayed low toxicity in the dark while being higher in the dark and higher in the presence of light | [ | |
|
| |||||||
| Cervical | SWCNTs | chitosan and folic acid, FITC | — | Functional SWCNTs chitosan conjugate for tumor cell targeting | Human cervical carcinoma HeLa cells | Conjugates provide new options for targeted drug delivery and tumor cell sensing because of the combined intrinsic properties of CNTs and the versatility of chitosan | [ |
| MWCNTs | Folate and iron | Doxorubicin | Folate and iron defunctionalized MWCNTs as dual targeted drug nanocarrier to cancer cells. | HeLa cells | This dual targeted nanocarrier has efficient biological and magnetical targeting capabilities towards HeLa cells and considered safe for biological applications. | [ | |
|
| |||||||
| Cervical | SWCNT, MWCNT | Acid-treated SWCNTs, acid-treated MWCNTs, amylose wrapped SWCNTs. | — | The influence of CNT scaffolds on human cervical carcinoma HeLa cells viability and focal adhesion kinase expression. | HeLa cells | Cells cultured on SWCNTs and on acid-treated SWCNTs were found to undergo apoptosis. The cells cultured on MWCNTs, acid-treated MWCNTs, and amylose wrapped SWCNTs were found to be viable. This may be due to focal adhesion kinases (FAK) expression which is responsible for controlling the cell viability | [ |
| SWCNTs | Polysaccharides [sodium alginate (ALG) and chitosan (CH)] | Doxorubicin (DOX) | Targeted delivery and controlled release by doxorubicin to cancer cells using modified CNTs. | HeLa cells | The DOX released from the modified nanotubes has been shown to damage nuclear DNA and inhibit the cell proliferation. | [ | |
|
| |||||||
| Prostate | SWCNTs | Polyethylenimine (PEI), Asn-Gly-Arg (NGR) peptide | SiRNA | Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized SWCNTs. | Human prostate carcinoma (GIV) cell PC-3 cells | SWCNT-PEI-SiRNA-NGR induces severe apoptosis and suppresses the proliferating of PC-3 cells without any level of toxicity | [ |